0001493152-26-018954
SEC filingIndaptus Therapeutics appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent Class II directors effective April 22, 2026, and accepted Matthew McMurdo's resignation as director on the same date.
The appointments of Tim Ruan and Dr. Johnny Fox Arrowsmith strengthen the Board's expertise in finance, capital markets, and intellectual property, critical for a biotechnology company navigating IPOs, M&A, and IP protection. Ruan's audit committee financial expert status enhances oversight of financial reporting and compliance. McMurdo's resignation appears routine without any indicated issues. Independent director agreements and indemnification provide standard governance protections, with modest $30,000 retainers signaling cost-conscious compensation amid board refresh with recent Class III additions.